Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note released on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ:CARA opened at $0.25 on Friday. The stock’s 50 day moving average price is $0.31 and its 200 day moving average price is $0.48. The company has a market capitalization of $13.70 million, a PE ratio of -0.11 and a beta of 0.70. Cara Therapeutics has a 52-week low of $0.24 and a 52-week high of $1.65.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. As a group, sell-side analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,935,718 shares of the biopharmaceutical company’s stock after buying an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned 3.54% of Cara Therapeutics worth $499,000 as of its most recent SEC filing. Institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.